Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Bolsa de Madrid  >  Grifols SA       ES0171996012

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials (€)
Sales 2017 4 371 M
EBIT 2017 1 132 M
Net income 2017 666 M
Debt 2017 4 881 M
Yield 2017 1,39%
Sales 2018 4 606 M
EBIT 2018 1 238 M
Net income 2018 756 M
Debt 2018 4 526 M
Yield 2018 1,59%
P/E ratio 2017 27,50
P/E ratio 2018 24,22
EV / Sales2017 4,95x
EV / Sales2018 4,62x
Capitalization 16 766 M
More Financials
Company
Grifols SA is a vertically integrated global producer of plasma derivatives.Its activities include sourcing raw material, manufacturing various plasma derivative products and selling and distributing final products to healthcare providers.The company operates through the following segments: ... 
Sector
Pharmaceuticals
Calendar
08/03Earnings Release
More about the company
Surperformance© ratings of Grifols SA
Trading Rating : Investor Rating :
More Ratings
Latest news on GRIFOLS SA
06/14 GRIFOLS : Beckman Coulter Enter Exclusive Distribution Agreement
05/30 GRIFOLS SA : ex-dividend day for final dividend
05/23 GRIFOLS : Makes Procleix Zika Virus Assay Available for Screening Blood Donation..
05/10 GRIFOLS : Investigational New Drug Application is Now Effective for Babesia Scre..
05/09 GRIFOLS : Company invests $2.5 million in Victoria plasma center
05/08 GRIFOLS : Company invests $2.5 million into Victoria plasma center
05/03 GRIFOLS : Bioscience Division sales increase 15% to drive Grifols’ revenue..
04/26 ORASURE TECHNOLOGIES : Grifols Strengthens Position as Global Provider of Diagno..
04/08 Spanish stock market rises 0.35%, closes at 10,361 points
04/06 ARADIGM : Announces Fourth Quarter 2016 and Full Year Financial Results
More news
Sector news : Biopharmaceuticals
06/22 GSK'S NEW CEO AIMS TO DIVEST SPORTS : sources
06/22 MYLAN : shareholders vote against executive pay, re-elect board
06/22 Health stocks help European equities cut losses
06/22DJR. JOHNSON : Missouri Sues Drug Firms Over Opioid Marketing -- WSJ
06/21DJJOHNSON & JOHNSON : J&J Seeking Dismissal of Talc Lawsuits in Missouri
More sector news : Biopharmaceuticals
News from SeekingAlpha
2016 Midday Gainers / Losers
2015 Tracking John Paulson's Paulson & Company Portfolio - Q3 2015 Update
2015 TiGenix Achieves First Ever Success In Allogeneic Stem Cell Phase 3 Trial
2015 Tracking John Paulson's Paulson & Company Portfolio - Q2 2015 Update
2015 Tracking John Paulson's Paulson & Company Portfolio - Q1 2015 Update
Advertisement
Income Statement Evolution
More Financials
Consensus 
Mean consensus HOLD
Number of Analysts 24
Average target price 24,5 €
Spread / Average Target -8,4%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Raimon Grifols Roura Joint Chief Executive Officer & Director
Victor Grifols Deu Joint Chief Executive Officer & Executive Director
Víctor Grifols Roura Non-Executive Chairman
Alfredo Arroyo Guerra Chief Financial Officer & Vice President
Vicente Blanquer Torre Vice President-Quality, Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GRIFOLS SA18 720
BIOGEN7.36%59 513
CSL LIMITED38.93%48 313
ALEXION PHARMACEUTICAL..3.17%28 346
GRIFOLS SA41.95%18 720
BIOMARIN PHARMACEUTICA..17.17%16 936
More Results